Auraptene (Synonyms: 橙皮油素)

目录号: HY-N2388 纯度: 99.96%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Auraptene 是一种口服有效的可以从芸香科植物中分离得到的香叶氧基香豆素，具有抗炎、抗细菌、抗病原体、抗氧化、抗肿瘤和神经保护等作用，在多种慢性疾病 (高血压、囊性纤维化) 治疗领域发挥重要作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Auraptene Chemical Structure

CAS No. : 495-02-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥561	In-stock
1 mg	￥171	In-stock
5 mg	￥500	In-stock
10 mg	￥800	In-stock
25 mg	￥1363	In-stock
50 mg	￥2000	In-stock
100 mg	￥3200	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Auraptene:

Auraptene (Standard) 询价

Auraptene 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看所有亚型

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

查看 PPAR 亚型特异性产品:

查看所有亚型

PPARα PPARβ/δ PPARγ PPAR PPARδ

生物活性
纯度 & 产品资料
参考文献

生物活性

Auraptene is an orally active geranyloxycoumarin that can be isolated from plants in the Brassicaceae family, antibacterial, anti-pathogen, antioxidant, anti-tumor, and neuroprotective effects. Auraptene plays an important role in the treatment of various chronic diseases such as hypertension and cystic fibrosis^[1][2].

IC₅₀ & Target^[1]

MMP-2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	82 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
BT-549	IC₅₀	24 μM Compound: 7	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
HT-29	IC₅₀	> 500 μM Compound: 8, Auraptene	Anticancer activity against human HT-29 cells after 72 hrs by MTT assay Anticancer activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19054677]
Jurkat	IC₅₀	55.36 μg/mL Compound: Auraptene	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
LoVo	IC₅₀	66 μM Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MDA-MB-231	IC₅₀	80 μM Compound: 7	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
MDCK	CC₅₀	7 μM Compound: 13a	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28501512]
PC-3	IC₅₀	65 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-MEL-28	IC₅₀	87 μM Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
T47D	IC₅₀	10.2 μM Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
T47D	IC₅₀	18.8 μM Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
U-373MG ATCC	IC₅₀	82 μM Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]

体外研究
(In Vitro)

Auraptene (0-20 μM, 2 h) 减少口腔上皮细胞中脂多糖刺激的炎症介质分泌并通过促进细胞迁移来促进伤口愈合^[1]。
Auraptene (10 μM, 24 h) 通过降低细胞周期蛋白 D1 蛋白表达和抑制 IGF-1 来抑制人乳腺癌细胞系 MCF-7 细胞周期进程^[2]。
Auraptene (10 μM, 4 天) 对 MRC-5 细胞中的人冠状病毒 OC43 具有抗病毒活性^[6]。
Auraptene (25-400 μM) 通过防止红细胞胞质抗氧化剂 GSH 的消耗并抑制蛋白质过氧化来保护自由基诱导的红细胞损伤^[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1].

Cell Line:	Oral epithelial cell line GMSM-K
Concentration:	0-20 μM
Incubation Time:	2 h
Result:	Didn't affect the survival rate of epithelial cells.

Real Time qPCR^[2].

Cell Line:	MCF-7 cell
Concentration:	10 μM
Incubation Time:	24 h
Result:	Upregulated gene expression levels of CDKN2B (Cyclin dependent kinase inhibitor 2B), DDIT3 (DNA damage inducible transcript 3), and JUN (JUN oncogene).

Real Time qPCR^[6].

Cell Line:	HCoV-OC43-infected human lung fibroblast MRC-5 cells
Concentration:	10 μM
Incubation Time:	4 days
Result:	Decreased viral RNA levels in HCoV-OC43-infected cells.

体内研究
(In Vivo)

Auraptene (200, 500 ppm, 混合在饮食中, 口服) 通过抑制细胞周期蛋白 D1 蛋白来延缓乳腺癌大鼠的肿瘤进展^[3]。
Auraptene (100, 500 ppm, 混合在饮食中, 口服) 通过减少 C57BL/6 小鼠中幽门螺杆菌的定植和促炎介质的产生来减轻胃炎^[4]。
Auraptene (5, 50 mg/kg, 6 周, 口服) 通过激活大鼠的过氧化物酶体增殖物激活受体 α (PPARα) 来预防心肌梗塞引起的心力衰竭^[5]。
Auraptene (2, 4, 8, 16 mg/kg, 5 周, 口服) 通过降低平均收缩压对高血压大鼠具有抗高血压作用^[8]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mammary carcinogenesis model in female Sprague Dawley rats^[3].
Dosage:	200, 500 ppm
Administration:	Oral gavage (p.o.); mixed in the diet
Result:	Delayed median time to tumor by 39 days and reduced Insulin like Growth Factor-1 (IGF-1, 10 ng/mL)-induced cyclin D1 expression by 40% in MCF-7 cells.

Animal Model:	Female C57BL/6 mice^[4].
Dosage:	100, 500 ppm
Administration:	Oral gavage (p.o.); mixed in the diet
Result:	Inhibited H. pylori–induced expression and/or production of CD74, macrophage migration inhibitory factor, interleukin-1b, and tumor necrosis factor-a in gastric mucosa, together with serum macrophage inhibitory protein-2.

Animal Model:	Sprague–Dawley rats with moderate myocardial infarction^[5].
Dosage:	5, 50 mg/kg
Administration:	Oral gavage (p.o.); 6 weeks
Result:	Suppresses PE-induced hypertrophic responses in cardiomyocytes. Prevented the development of cardiac hypertrophy and fibrosis in rats with myocardial infarction.

Animal Model:	Desoxycorticosterone acetate (DOCA) salt induced hypertensive rats^[8].
Dosage:	2, 4, 8, 16 mg/kg
Administration:	Oral gavage (p.o.); 5 weeks
Result:	Reduced the mean systolic blood pressure (MSBP) in DOCA salt treated rats.

分子量

298.38

Formula

C₁₉H₂₂O₃

CAS 号

495-02-3

性状

固体

颜色

Off-white to light yellow

中文名称

橙皮油素；橙油素；橙皮油内酯

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (167.57 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3514 mL	16.7572 mL	33.5143 mL
5 mM	0.6703 mL	3.3514 mL	6.7029 mL
10 mM	0.3351 mL	1.6757 mL	3.3514 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.97 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.97 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.97 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.96%

选择批次：

Data Sheet (647 KB) SDS (393 KB)

COA (280 KB) HNMR (184 KB) RP-HPLC (151 KB)

产品使用指南 (1538 KB)

参考文献

[1]. La VD, et al. Anti-inflammatory and wound healing potential of citrus auraptene. J Med Food. 2013 Oct;16(10):961-4. [Content Brief]

[2]. Krishnan P, et al. Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7. Int J Breast Cancer. 2012;2012:502092. [Content Brief]

[3]. Krishnan P, et al. Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. BMC Cancer. 2009 Jul 29;9:259. [Content Brief]

[4]. Sekiguchi H, et al. Auraptene attenuates gastritis via reduction of Helicobacter pylori colonization and pro-inflammatory mediator production in C57BL/6 mice. J Med Food. 2012 Jul;15(7):658-63. [Content Brief]

[5]. Sunagawa Y, et al. Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats. Phytomedicine. 2022 Dec;107:154457. [Content Brief]

[6]. Min JS, et al. Auraptene Has Antiviral Activity against Human Coronavirus OC43 in MRC-5 Cells. Nutrients. 2023 Jun 29;15(13):2960. [Content Brief]

[7]. Jamialahmadi K, et al. Protective Effects of Auraptene against Free Radical-Induced Erythrocytes Damage. J Pharmacopuncture. 2022 Dec 31;25(4):344-353. [Content Brief]

[8]. Razavi BM, et al. Antihypertensive effect of auraptene, a monoterpene coumarin from the genus Citrus, upon chronic administration. Iran J Basic Med Sci. 2015 Feb;18(2):153-8. [Content Brief]

Auraptene 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3514 mL	16.7572 mL	33.5143 mL	83.7858 mL
	5 mM	0.6703 mL	3.3514 mL	6.7029 mL	16.7572 mL
	10 mM	0.3351 mL	1.6757 mL	3.3514 mL	8.3786 mL
	15 mM	0.2234 mL	1.1171 mL	2.2343 mL	5.5857 mL
	20 mM	0.1676 mL	0.8379 mL	1.6757 mL	4.1893 mL
	25 mM	0.1341 mL	0.6703 mL	1.3406 mL	3.3514 mL
	30 mM	0.1117 mL	0.5586 mL	1.1171 mL	2.7929 mL
	40 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0946 mL
	50 mM	0.0670 mL	0.3351 mL	0.6703 mL	1.6757 mL
	60 mM	0.0559 mL	0.2793 mL	0.5586 mL	1.3964 mL
	80 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	100 mM	0.0335 mL	0.1676 mL	0.3351 mL	0.8379 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Auraptene495-02-3橙皮油素橙油素橙皮油内酯MMPPPARBacterialMatrix metalloproteinasesPeroxisome proliferator-activated receptorsantioxidantneuroprotectionMCF-7hypertensive ratsInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Auraptene (Synonyms: 橙皮油素)

Customer Review

Other Forms of Auraptene:

Auraptene 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看 PPAR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Auraptene 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Auraptene (Synonyms: 橙皮油素)

Customer Review

Other Forms of Auraptene:

Auraptene 相关抗体

Auraptene 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看 PPAR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Auraptene 相关抗体:

摩尔计算器

稀释计算器

Auraptene 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z